NEOGENOMICS Business Summary

NeoGenomics Inc. (NEO) operates a high-complexity clinical laboratory network specializing in cancer genetics and diagnostic testing. The company generates revenue primarily through a fee-for-service model across two core business segments: Clinical Services, which provides specialized oncology testing to community-based pathologists, oncologists, and hospitals, and Pharma Services, which offers contract research and clinical trial support to pharmaceutical companies. As of early 2026, the company has pivoted its strategic focus toward high-value, therapy-guided testing, specifically leveraging its proprietary RaDaR and PanTracer liquid biopsy platforms to drive Average Unit Price (AUP) expansion. NeoGenomics competes directly with large-scale diagnostic providers like Quest Diagnostics and Labcorp, as well as specialized genomic firms such as Guardant Health and Exact Sciences. It distinguishes itself as the market leader in the community oncology setting—where approximately 80% of cancer care is delivered—and maintains a dominant position in hematology testing with a market share exceeding 25%. Originally founded in 2002 by Dr. Michael Dent, NeoGenomics is currently led by a seasoned executive team with deep roots in the biopharma and diagnostics industries. Chief Executive Officer Tony Zook, who assumed the role in April 2025, previously served as an Executive Vice President at AstraZeneca and CEO of Innocoll Biotherapeutics. The financial leadership transitioned in March 2026 to Chief Financial Officer Abhishek Jain, a veteran of CareDx and Agilent Technologies, while Warren Stone serves as President and Chief Operating Officer. The company’s digital and innovation strategy is overseen by Chief Digital and Information Officer Elizabeth Floegel and Chief Innovation Officer Dr. Andrew Lukowiak. The Board of Directors, chaired by Lynn Tetrault, recently added industry veteran Jack Kenny (former CEO of Meridian Bioscience) to bolster its commercial expertise. Major institutional backers include First Light Asset Management, Millennium Management, and T. Rowe Price, reflecting strong investor confidence in the company’s transition toward a high-margin, NGS-driven diagnostic portfolio.